TROG 92.01 - PCNSL (Phase II) - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

TROG 91.01 – Head & Neck – Accelerated RT

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000

TROG 92.01 – PCNSL (Phase II)

A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

TROG 91.01 – Head & Neck – Accelerated RT

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000